Universe Pharmaceuticals : Results of the Universe Pharmaceuticals INC 2023 Annual General Meeting - Form 6-K
July 05, 2023 at 04:35 pm
Share
Results of the Universe Pharmaceuticals INC 2023 Annual General Meeting
At the 2023 annual general meeting of shareholders (the "Meeting") of Universe Pharmaceuticals INC (the "Company") held at 10:00 a.m. Beijing Time on July 3, 2023, the shareholders of the Company adopted resolutions approving all of the ten proposals considered at the Meeting. A total of 71.54% of the 21,750,000 votes exercisable as of May 24, 2023, the record date, were present in person or by proxy at the Meeting. The results of the votes were as follows:
1.
As an ordinary resolution, that Gang Lai be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal One")
Resolution
For
Against
Abstain
Proposal One
15,432,870
123,217
2,840
Percentage of Voted Shares:
99.21
%
0.79
%
2.
As an ordinary resolution, that Lin Yang be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal Two")
Resolution
For
Against
Abstain
Proposal Two
15,427,876
128,216
2,835
Percentage of Voted Shares:
99.18
%
0.82
%
3.
As an ordinary resolution, that Jiawen Pang be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal Three")
Resolution
For
Against
Abstain
Proposal Three
15,428,871
127,221
2,835
Percentage of Voted Shares:
99.18
%
0.82
%
4.
As an ordinary resolution, that Ding Zheng be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal Four")
Resolution
For
Against
Abstain
Proposal Four
15,427,871
128,221
2,835
Percentage of Voted Shares:
99.18
%
0.82
%
5.
As an ordinary resolution, that Yongping Yu be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal Five")
Resolution
For
Against
Abstain
Proposal Five
15,428,900
127,192
2,835
Percentage of Voted Shares:
99.18
%
0.82
%
6.
As an ordinary resolution, that the Company's authorized share capital, effective immediately, be increased from US$312,500 divided into 90,000,000 Ordinary Shares of par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 Ordinary Shares of par value US$0.003125 each and 100,000,000 Preferred Shares of par value US$0.003125 each ("Proposal Six")
Universe Pharmaceuticals Inc. published this content on 05 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 July 2023 20:34:46 UTC.
Universe Pharmaceuticals Inc is a China-based holding company mainly engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (TCMD) products targeting the elderly. Through its subsidiary, the Company sells TCMD products, biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. Its TCMD products fall into two categories: chronic condition treatments as well as cold and flu medications, including Guben Yanling Pill, Shenrong Weisheng Pill, Fengshitong Medicinal Liquor, Isatis Root Granule and Qiangli Pipa Syrup. Its major customers are pharmaceutical companies, hospitals, clinics and drugstore chains. The Company mainly conducts its businesses within the Chinese market.
UNIVERSE PHARMACEUTICALS INC 
